A Double-blind, Placebo-controlled Study to Assess the Effects of Inhaled PC945 in the Treatment of Culture-positive Aspergillus or Candida Fungal Bronchitis in Subjects With Moderate to Severe Asthma or Other Chronic Respiratory Diseases
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs PC 945 (Primary)
- Indications Aspergillosis
- Focus Therapeutic Use
- Sponsors Pulmocide
- 10 Apr 2019 Planned End Date changed from 30 Jun 2019 to 28 Feb 2020.
- 10 Apr 2019 Planned primary completion date changed from 30 Apr 2019 to 31 Dec 2019.
- 27 Nov 2018 New trial record